NCT03120494View on ClinicalTrials.gov

Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B

PHASE4UnknownINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2019

Study Completion Date

November 30, 2019

Conditions

HIV/AIDS

Interventions

DRUG

Emtricitabine and Tenofovir

All subjects will be provided study drug for use daily for one year.

Trial Locations (1)

00928

Puerto Rico Community Network for Clinical Research on AIDS (PR-CoNCRA), San Juan

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Puerto Rico Community Network for Clinical Research on AIDS

OTHER

NCT03120494 - Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B | Biotech Hunter | Biotech Hunter